Lipitor vs Crestor: Head-to-Head Efficacy Comparison

How These Two Statins Compare in LDL Lowering

Rosuvastatin produces a larger LDL reduction per milligram than atorvastatin. The STELLAR trial (N=2,431) randomized patients across dose ranges of both drugs and found rosuvastatin 10 mg lowered LDL by 45.8%, matching atorvastatin 20 mg (42.6%) and outperforming atorvastatin 10 mg (36.8%) 1. At the highest tested doses, rosuvastatin 40 mg achieved a 55.0% LDL reduction versus 51.1% for atorvastatin 80 mg 1.

This potency gap matters for dose selection. A patient needing a 50% LDL cut can reach that target with rosuvastatin 20 mg or atorvastatin 80 mg. The clinical translation is straightforward: rosuvastatin achieves equivalent or greater LDL lowering at half the milligram dose. The 2018 ACC/AHA cholesterol guideline defines high-intensity statin therapy as treatment expected to lower LDL by 50% or more, and both drugs clear that bar (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) 2.

The VOYAGER meta-analysis pooled individual patient data from 32,258 participants across 37 trials and confirmed this dose-response relationship across both statins 3. For non-HDL cholesterol and apolipoprotein B, the pattern held: rosuvastatin showed greater reductions at equivalent milligram doses. Yet the guideline framework does not prefer one over the other. Both sit in the same high-intensity tier. The distinction is pharmacological, not therapeutic.

Cardiovascular Outcomes: ASCOT-LLA and JUPITER

Neither drug has beaten the other in a head-to-head cardiovascular outcomes trial. What exists instead are two separate placebo-controlled studies with different patient populations.

The ASCOT-LLA trial (N=10,305) tested atorvastatin 10 mg against placebo in hypertensive patients with at least three additional cardiovascular risk factors but no prior coronary disease 4. The trial was stopped early at a median 3.3 years after atorvastatin produced a 36% relative risk reduction in primary coronary events (HR 0.64, 95% CI 0.50-0.83, P=0.0005). Fatal and non-fatal stroke dropped by 27%.

JUPITER (N=17,802) enrolled apparently healthy men 50 and older and women 60 and older with LDL <130 mg/dL but hsCRP of 2.0 mg/L or higher 5. Rosuvastatin 20 mg reduced the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death by 44% (HR 0.56, 95% CI 0.46-0.69, P<0.00001). The trial was also stopped early, at a median follow-up of 1.9 years.

Comparing these numbers directly is misleading. ASCOT-LLA used a low statin dose (atorvastatin 10 mg) in higher-risk patients. JUPITER used a full therapeutic dose (rosuvastatin 20 mg) in a population with lower baseline LDL but elevated inflammatory markers. The 36% vs 44% risk reduction figures reflect different patient populations, different doses, different endpoints, and different trial durations. They do not constitute a head-to-head comparison.

Dr. Paul Ridker, the principal investigator of JUPITER, stated in the original publication: "Among apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events" 5. This finding expanded statin eligibility to a new patient group rather than proving rosuvastatin's superiority over other statins.

The SATURN Trial: Atherosclerosis Regression Compared Directly

The closest thing to a head-to-head efficacy comparison is the SATURN trial (N=1,039), which used intravascular ultrasound (IVUS) to measure coronary plaque regression with rosuvastatin 40 mg versus atorvastatin 80 mg over 104 weeks 6.

Rosuvastatin 40 mg lowered LDL to a mean of 62.6 mg/dL, compared with 70.2 mg/dL for atorvastatin 80 mg (P<0.001). Rosuvastatin also raised HDL more (12.8 mg/dL increase vs 8.5 mg/dL). But the primary endpoint, percent atheroma volume (PAV), showed no statistically significant difference between the two drugs. Both produced regression: rosuvastatin reduced PAV by 1.22% and atorvastatin by 0.99% (P=0.17 for between-group comparison) 6.

The SATURN investigators concluded that despite the lipid differences, "the degree of atherosclerosis regression was similar with both agents." This trial is the strongest available evidence that greater LDL lowering with rosuvastatin does not automatically translate into greater plaque benefit. The arteries responded comparably.

One secondary endpoint did favor rosuvastatin. Total atheroma volume decreased by 6.39 mm³ with rosuvastatin versus 4.20 mm³ with atorvastatin (P=0.01). This measure captures absolute plaque burden rather than percent change, and the difference, while statistically significant, has uncertain clinical meaning without long-term event data.

Pharmacokinetic Differences That Influence Prescribing

Atorvastatin is metabolized primarily through the CYP3A4 enzyme pathway, making it susceptible to drug interactions with CYP3A4 inhibitors like clarithromycin, itraconazole, and certain HIV protease inhibitors 7. Rosuvastatin undergoes minimal hepatic metabolism (about 10% via CYP2C9), and is largely excreted unchanged. This gives rosuvastatin a cleaner interaction profile for patients on complex medication regimens.

Atorvastatin has a half-life of approximately 14 hours, while rosuvastatin's half-life is about 19 hours 7. Both are long enough that dosing time (morning vs evening) makes minimal practical difference. Some older, shorter-acting statins like simvastatin require evening dosing to coincide with peak nocturnal cholesterol synthesis, but neither atorvastatin nor rosuvastatin shares that limitation.

Atorvastatin is lipophilic. Rosuvastatin is hydrophilic. This physicochemical difference affects tissue penetration. Hydrophilic statins are more hepato-selective (they concentrate in the liver, their target organ) and show lower skeletal muscle penetration in preclinical models. Whether this translates into a meaningful difference in myalgia rates is debated, though some observational data suggests rosuvastatin causes fewer muscle complaints 8.

What the Guidelines Actually Recommend

The 2018 ACC/AHA Multisociety Guideline on the Management of Blood Cholesterol does not recommend one statin over another within the same intensity tier 2. For patients requiring high-intensity therapy (those with clinical atherosclerotic cardiovascular disease, LDL 190 mg/dL or above, or diabetes with multiple risk factors), the guideline lists atorvastatin 40-80 mg and rosuvastatin 20-40 mg as equivalent first-line options.

The guideline writing committee noted: "For each intensity category, the evidence is insufficient to recommend one statin over another" 2. This position has not changed in subsequent focused updates from the ACC.

The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) 2019 dyslipidemia guidelines adopt a similar stance but push LDL targets lower (below 55 mg/dL for very-high-risk patients) 9. At these aggressive targets, the milligram-for-milligram potency advantage of rosuvastatin can matter. A patient who reaches an LDL of 65 mg/dL on atorvastatin 80 mg may hit 55 mg/dL by switching to rosuvastatin 40 mg, potentially avoiding the addition of ezetimibe or a PCSK9 inhibitor.

Cost and Access Considerations

Both atorvastatin and rosuvastatin are available as generics. Cash prices for a 30-day supply of generic atorvastatin typically range from $4 to $15 at most U.S. pharmacies, and generic rosuvastatin runs from $10 to $30, depending on dose and retailer 10. Atorvastatin went generic in 2011, rosuvastatin in 2016, so atorvastatin has had more time for price competition to drive costs down.

Insurance formulary placement varies. Some plans place one statin on a preferred tier with a lower copay. For patients facing a cost differential, the clinical data supports either drug as a valid option. A 2014 Cochrane review of statin class effects found no evidence that any single statin within the same intensity class produced superior cardiovascular outcomes 11.

Safety and Tolerability Profile

Both drugs share the class-wide statin safety profile. Myalgia occurs in 5-10% of statin users across observational studies, though randomized trial data from SAMSON (N=60) demonstrated that two-thirds of statin side effects were attributable to the nocebo effect 12. Rhabdomyolysis is rare (about 1 in 10,000 patient-years) with either drug.

Hepatotoxicity monitoring has changed. The FDA removed the requirement for routine liver function testing during statin therapy in 2012, noting that serious liver injury is rare and unpredictable 10. Baseline hepatic transaminase measurement is still recommended before starting therapy.

Rosuvastatin carries a labeled caution for patients of Asian descent. Pharmacokinetic studies show approximately twofold higher plasma concentrations in Asian populations, prompting the FDA-approved labeling to recommend a starting dose of 5 mg in these patients 7. Atorvastatin's labeling does not include a similar dose adjustment.

Both statins are associated with a small increase in new-onset type 2 diabetes. A meta-analysis of 13 statin trials (N=91,140) found statins increased diabetes risk by 9% (OR 1.09, 95% CI 1.02-1.17), with higher-intensity regimens carrying modestly greater risk 13. JUPITER specifically reported a higher rate of physician-reported diabetes in the rosuvastatin group (3.0% vs 2.4%, P=0.01), though the cardiovascular benefit far outweighed this risk 5.

When Clinicians Choose One Over the Other

Prescribing patterns reflect practical rather than efficacy-driven decisions. A physician treating a patient on a CYP3A4 inhibitor (say, diltiazem for atrial fibrillation) will often prefer rosuvastatin to avoid the interaction. A physician treating a cost-sensitive patient without insurance may lean toward atorvastatin because generic pricing is lower.

For patients who have not reached their LDL goal on moderate-intensity atorvastatin 20 mg, the decision branches. Increasing to atorvastatin 40-80 mg provides an additional 6-8% LDL reduction (the "rule of 6" for statin dose doubling). Switching to rosuvastatin 20-40 mg may provide a larger incremental drop due to the potency difference. A 2016 network meta-analysis (N=83,000 across 51 trials) estimated that rosuvastatin 20 mg and atorvastatin 40 mg produce overlapping LDL reductions, but rosuvastatin 40 mg outperforms atorvastatin 80 mg by roughly 4 percentage points 14.

In patients with chronic kidney disease (eGFR 30-59 mL/min/1.73 m²), dose adjustment is recommended for rosuvastatin (maximum 10 mg if eGFR <30) but not for atorvastatin. This renal dosing restriction can shift the choice toward atorvastatin in patients with significant kidney impairment 7.

Making the Clinical Decision

The best statin is the one a patient will take consistently. Adherence data from a 2017 retrospective cohort study (N=68,054) found that 12-month statin persistence rates averaged 55-60% regardless of which statin was prescribed 15. The choice between atorvastatin and rosuvastatin affects LDL numbers at the margin but has not been shown to produce different rates of heart attack or stroke in a controlled comparison.

For patients needing the absolute maximum LDL reduction from a single agent, rosuvastatin 40 mg delivers about 4 percentage points more LDL lowering than atorvastatin 80 mg. For patients requiring a high-intensity statin with fewer drug interaction concerns, rosuvastatin has the pharmacokinetic advantage. For patients prioritizing cost or requiring no renal dose adjustment, atorvastatin may be the simpler option.

The ACC's 2018 guideline risk calculator does not distinguish between the two drugs in its treatment recommendations. Once high-intensity statin therapy is indicated, the prescriber chooses based on the patient's medication list, kidney function, ancestry-based dosing considerations, formulary availability, and individual tolerability history. Both drugs sit at the top of the efficacy hierarchy for their class, and the 30+ year statin evidence base supports either one for reducing cardiovascular events in indicated populations 2.